Table 2.
Comparisons of cumulative incidence of HCC and HR between treatment groups.
| Treatment | HCC (%) | Cumulative incidence (%) | Incidence rate* | log-rank P value |
Univariable Cox regression | E value (lower**) |
|||
|---|---|---|---|---|---|---|---|---|---|
| 2-year | 3-year | 5-year | Crude HR (95% CI) | P value | |||||
| All (n = 2,889) | 97 (3.4) | 1.5 | 3.1 | 6.2 | 10.4 | 0.135 | - | - | - |
| BSV (n = 486) | 6 (1.2) | 1.2 | 1.2 | 1.8 | 4.3 | - | Reference | - | - |
| ETV (n = 852) | 38 (4.5) | 1.2 | 3.6 | 6.8 | 12.5 | 0.026 | 2.627 (1.103, 6.255) | 0.029 | 4.694 (1.441) |
| TAF (n = 801) | 21 (2.6) | 1.7 | 3.4 | 7.4 | 9.2 | 0.086 | 2.191 (0.884, 5.434) | 0.090 | NA |
| TDF (n = 750) | 32 (4.3) | 1.9 | 3.4 | 6.9 | 12.3 | 0.028 | 2.623 (1.090, 6.311) | 0.031 | 4.686 (1.403) |
*Incidence rate, per 1000 person-years.
**lower confidence limit.
Abbreviation: HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; BSV, besifovir dipivoxil maleate; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.